Unknown Analyst

Analyst working for Jason Zemansky. Welcome to the first day of the Annual Bank of America Vegas Healthcare Conference. We want to welcome Geron Corp. With me, I have -- sorry, I have Harout Semerjian, CEO; as well as Joe Eid, CMO. Welcome, guys.

Harout Semerjian
CEO, President & Director

Thank you very much, Jackie.

Unknown Analyst

Great. So just to get us started, maybe to start broadly for those less familiar with Geron, can you give a quick overview of the story and your focus on blood cancers?

Harout Semerjian
CEO, President & Director

Sure, of course. And thank you for Bank of America for this invitation. Very happy to be here today sharing why we're excited at Geron as we progress with the company. So Geron is a company that has graduated to be a commercial stage company, really battling hematological diseases. We have launched our first asset, which is a telomerase inhibitor called imetelstat, RYTELO is the trade name, really trying to help more and more lower-risk MDS patients around the world. And now it's been about 18 months or so that we have launched, and we continue to grow and which is something we're really proud of.

So as a company, we are very excited to be growing and helping more and more patients in lower-risk MDS as the first indication, but also we do have another indication, hopefully, that would have a readout in myelofibrosis as an interim in the second half of this year. So we can -- I'm sure we're going to talk about that as well.